MaxCyte Appoints Cynthia Collins to its Board of Directors
15 Octobre 2024 - 2:05PM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, today announced the
appointment of Cynthia Collins to the Company’s Board of Directors
as a non-executive director, effective October 14, 2024. Collins
will serve on the board’s compensation committee. Following her
appointment, MaxCyte’s total Board of Directors will increase to 10
members.
“I am pleased to welcome Cynthia to MaxCyte’s
Board of Directors,” said Maher Masoud, President and CEO of
MaxCyte. “Cynthia has extensive and impressive leadership
experience in the fields of cell therapy and genetic medicine that
will be invaluable to MaxCyte in the coming years. I look forward
to working alongside her to enable a growing set of next-generation
cell therapies as the premier cell engineering platform in our
industry.”
Ms. Collins brings over 40 years of experience
in the biotechnology industry and cell and gene medicines to
MaxCyte, including her most recent role as Chief Executive Officer
of Editas Medicine, where she was involved in dosing the first
patient ever with an in-vivo gene modified therapy. Previously, Ms.
Collins served as Chief Executive Officer of Human Longevity Inc.,
Chief Executive Officer/General Manager of General Electric
Healthcare’s Cell Therapy and Lab Businesses, and Chief Executive
Officer of GenVec, Inc., a vaccine and gene therapy company.
Currently, Ms. Collins serves as a member of the
Board of Directors of several healthcare companies, including
Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics
(Nasdaq: PSTX), Certara (Nasdaq: CERT), DermTech (OTC: DMTKQ),
Draper Laboratory, and Panavance Therapeutics. She is also a board
member of the Foundation for mRNA Medicines.
Cynthia Collins holds a Bachelor of Science
degree in Microbiology from the University of Illinois, Urbana and
an MBA from The University of Chicago Booth School of Business.
“I am honored to join MaxCyte’s Board of
Directors, where I believe there is exceptional work being done to
propel the cell and genetic medicine industry forward,” said
Cynthia Collins. “I am excited to support the Company’s growth and
innovation as they continue to help developers bring a new class of
therapies to market.”
Regulatory Disclosures
In accordance with Rule 17, Schedule Two
paragraph (g) of the AIM Rules for Companies, Cynthia Lynne Collins
(66) holds, or has held, the following directorship or partnerships
in the last five years:
Current |
Past 5 years |
Alanis Therapeutics, Inc. |
Triumvira Immunologics, Inc. |
Nutracker Therapeutics, Inc. |
Biocare Medical LLC |
Panavance Therapeutics, Inc. |
Human Longevity, Inc. |
The Charles Stark Draper Laboratory, Inc. |
Editas Medicine, Inc. |
Poseida Therapeutics, Inc. |
ARM Foundation for Cell and Gene Medicine |
Certara, Inc. |
|
DermTech Inc. |
|
The Foundation for MRNA Medicines, Inc. |
|
Cynthia Collins, was previously appointed as an
independent director to the Board of DermTech, Inc. on May 24,
2018. On June 18, 2024, the Company filed for Chapter 11
bankruptcy. On August 21, 2024 the US Bankruptcy Court for the
District of Delaware approved the sale of a substantial amount of
DermTech Inc.’s assets through a court-supervised auction.
Save as disclosed above, there is no further
information to be disclosed pursuant to Rule 17 Schedule Two
paragraph (g) of the AIM Rules for Companies in respect of the
appointment of Cynthia Collins.
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation® technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X and LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
US Media RelationsSpectrum
ScienceJordan Vinesjvines@spectrumscience.com+1
540-629-3137
Nominated Adviser and Joint Corporate
BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate
BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserICR
ConsiliumMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
MaxCyte (NASDAQ:MXCT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
MaxCyte (NASDAQ:MXCT)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024